Ken Mulvany

Ken Mulvany is the Executive Chairman of BenevolentAI, a leading AI-driven drug discovery company focused on transforming how medicines are developed. He returned to this leadership role in October 2024 to steer the company through a critical strategic renewal.

‍

Mulvany co-founded BenevolentAI in 2013 and previously served as its Chairman until July 2021. He played a vital role in building the company’s pioneering AI platform that achieved the first FDA approval for an AI-identified drug and formed partnerships with major pharmaceutical firms.

‍

Prior to founding BenevolentAI, Ken was CEO of Proximagen Group plc, a biotech firm specializing in neurodegeneration treatments, which was sold in 2012 for approximately US$553 million.

‍

He has also contributed to public strategy through advisory roles on the UK Government’s AI strategy board and for Oxford Sciences Innovation, guiding innovation at the intersection of AI and health. Outside of business, Ken chaired the Cure Parkinson’s Trust from 2013 to 2018, underlining his commitment to both innovation and philanthropy.

‍